Finance

Lists
Q3 2026 earnings • released • EPS beat +25.35% • Revenue beat +1.12%
See results
PODD:NASDAQ
Insulet Corp
$156.12
-5.39%
(-8.90) 1D
$156.12
0.00% (0.00)
After hours
Closed: Nov 5, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PODD...
Open
$167.33
High
$168.47
Low
$152.23
Mkt. cap
10.83B
Avg. vol.
1.56M
Volume
993.30K
P/E ratio
25.44
52-wk high
$354.88
52-wk low
$126.50
EPS
$6.14
Beta
1.06
Shares outstanding
69.35M
No. of employees
5K
Open
$167.33
High
$168.47
Low
$152.23
Mkt. cap
10.83B
Avg. vol.
1.56M
Volume
993.30K
P/E ratio
25.44
52-wk high
$354.88
52-wk low
$126.50
EPS
$6.14
Beta
1.06
Shares outstanding
69.35M
No. of employees
5K
News stories
From web sources and news partners
About Insulet Corp
CEOAshley Mcevoy
Employees5.4K
Founded2000
HeadquartersActon, Massachusetts, United States
SectorHealth Care
IndustryMedical device
Websiteinsulet.com
Analyst ratings
Based on 17 analysts giving stock ratings to PODD in the past 3 months
Buy
Buy
9
Hold
8
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for PODD in the last 3 months.
Highest
Current $156.12
$200.00 (+28.11%)
Average
$174.94 (+12.05%)
Lowest
$144.00 (-7.76%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mike Kratky
Leerink Partners
Hold
Maintained
$167.00
+7%
11/05/2026
Robbie Marcus
J.P. Morgan
Hold
Maintained
$170.00
+8.9%
11/05/2026
Patrick Wood
UBS
Hold
Reiterated
$171.00
+9.5%
11/05/2026
Joanne Wuensch
Citi
Hold
Maintained
$170.00
+8.9%
11/05/2026
Lee Hambright
Bernstein
Buy
Reiterated
$200.00
+28.1%
11/05/2026
Marie Thibault
BTIG
Hold
Maintained
-
-
11/04/2026
Christopher Pasquale
Barclays
Hold
Maintained
$150.00
-3.9%
11/05/2026
Jeff Johnson
Robert W. Baird
Buy
Maintained
$200.00
+28.1%
11/04/2026
Kendall Au
RBC Capital
Buy
Reiterated
$180.00
+15.3%
11/04/2026
Matthew Taylor
Jefferies
Buy
Maintained
$190.00
+21.7%
10/12/2026
Matt Miksic
Barclays
Hold
Maintained
$150.00
-3.9%
10/07/2026
Kieran Ryan
Deutsche Bank
Buy
Maintained
$180.00
+15.3%
08/06/2026
Bruce Jackson
StoneX
Buy
Maintained
$185.00
+18.5%
08/06/2026
Daniel Markowitz CFA
Evercore ISI
Buy
Maintained
$180.00
+15.3%
08/06/2026
Jonathan Block
Stifel Nicolaus
Buy
Reiterated
$180.00
+15.3%
08/06/2026
William Plovanic
Canaccord Genuity
Buy
Maintained
$179.00
+14.7%
08/06/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
$160.00
+2.5%
08/05/2026
Larry Biegelsen
Wells Fargo
Hold
Downgraded
$144.00
-7.8%
08/05/2026
Mathew Blackman
TD Cowen
Hold
Reiterated
$144.00
-7.8%
08/06/2026
Richard Newitter
Truist Financial
Hold
Downgraded
$153.00
-2%
08/06/2026
Steven Lichtman
William Blair
Buy
Maintained
-
-
08/05/2026
Suraj Kalia
Oppenheimer
Hold
Downgraded
-
-
08/05/2026
Danielle Antalffy
UBS
Hold
Downgraded
$174.00
+11.5%
07/28/2026
Unknown Analyst
Deutsche Bank
Buy
Initiated
$190.00
+21.7%
06/23/2026
Travis Steed
Bank of America Securities
Buy
Maintained
$208.00
+33.2%
06/23/2026
Matthew O'Brien
Piper Sandler
Buy
Maintained
$210.00
+34.5%
06/15/2026
Jayson Bedford
Raymond James
Buy
Maintained
$216.00
+38.4%
06/08/2026
David Roman
Goldman Sachs
Buy
Maintained
$205.00
+31.3%
05/27/2026
Andrew Ranieri
TD Cowen
Hold
Maintained
$294.00
+88.3%
05/06/2026
Issie Kirby
Rothschild & Co Redburn
Hold
Downgraded
$220.00
+40.9%
04/24/2026
Brandon Vazquez
William Blair
Buy
Maintained
-
-
02/18/2026
Last report
Nov 4, 2026
Fiscal period
Q3 2026
$1.99 / $1.59
+25.35%beat
Revenue / Est. (USD)
842.00M / 832.64M
+1.12%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
706.30M
783.80M
761.70M
801.70M
Cost of goods sold
196.20M
215.20M
232.70M
239.10M
Cost of revenue
196.20M
215.20M
232.70M
239.10M
Research and development expenses
77.20M
90.90M
89.70M
88.10M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
315.20M
331.40M
317.20M
344.80M
Operating expense
392.40M
422.30M
406.90M
432.90M
Total operating expenses
588.60M
637.50M
639.60M
672.00M
Operating income
117.70M
146.30M
122.10M
129.70M
Other non operating income
12.10M
1.20M
700.00K
-1.10M
EBT including unusual items
122.80M
140.10M
113.00M
118.70M
EBT excluding unusual items
122.80M
140.10M
113.00M
118.70M
Income tax expense
35.20M
38.50M
21.90M
23.70M
Effective tax rate
28.66%
27.48%
19.38%
19.97%
Other operating expenses
-
-
-
-
Net income
87.60M
101.60M
91.10M
95.00M
Net profit margin
12.40%
12.96%
11.96%
11.85%
Earnings per share
1.24
1.55
1.42
1.66
Interest and investment income
8.60M
5.70M
4.90M
3.60M
Interest expense
-15.60M
-14.90M
-14.70M
-13.50M
Net interest expenses
-7.00M
-9.20M
-9.80M
-9.90M
Depreciation and amortization charges
-
-
-
-
EBITDA
139.70M
170.70M
148.30M
156.40M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps